Clinical trial designs for prospective validation of biomarkers

Sumithra J. Mandrekar, Axel Grothey, Matthew P. Goetz, Daniel J. Sargent

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Traditionally, anatomic staging systems have been used to determine predictions of individual patient outcome and, to a lesser extent, guide the choice of treatment in patients with cancer. With new targeted therapies, the role of biomarkers is increasingly promising, suggesting an integrated approach using the genetic make-up of the tumor and the genotype of the patient for treatment selection and patient management. Specifically, biomarkers can aid in patient stratification (risk assessment), treatment response identification (surrogate markers), or in differential diagnosis (identifying individuals who are likely to respond to specific drugs). To be clinically useful, a marker must favorably affect clinical outcomes such as decreased toxicity, increased overall and/or disease-free survival, or improved quality of life. This paper focuses on possible clinical trial designs for assessing the utility of a predictive marker(s) for toxicity or clinical efficacy. We consider the scenario of single and multiple markers as well as present alternative solutions based on the prevalence of a marker. Our designs rest on the assumption that the methods for assessment of the biomarker are established and the initial results show promise with regard to the predictive ability of a marker. Additional research is clearly warranted to achieve the goal of 'predictive oncology'.

Original languageEnglish (US)
Pages (from-to)317-325
Number of pages9
JournalAmerican Journal of PharmacoGenomics
Volume5
Issue number5
DOIs
StatePublished - Oct 17 2005

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Clinical trial designs for prospective validation of biomarkers'. Together they form a unique fingerprint.

  • Cite this